Atossa Appoints Mark Daniel, CPA, as Chief Financial Officer to Lead Finance, Systems, and Capital Strategy for Commercial Readiness

Core Insights - Atossa Therapeutics has appointed Mark Daniel as Chief Financial Officer to support its transition to commercial operations with (Z)-endoxifen [1][3] - Daniel brings over 25 years of experience in life sciences finance, including revenue forecasting, public company controls, and capital markets expertise [1][2] - The company aims to focus on revenue-ready systems, disciplined spending, and milestone-aligned financing as it prepares for commercialization [3] Financial Management - Daniel has managed operating expense budgets exceeding $200 million and has implemented Sarbanes-Oxley (SOX) controls [1] - He has overseen a cash and investments portfolio of $400 million and executed nearly $1 billion in various financing transactions [2] - The company emphasizes disciplined capital allocation and aims to align spending with value-creating milestones [5] Operational Strategy - Atossa plans to operationalize commercial readiness through improved financial planning and analysis (FP&A), revenue forecasting, and capital planning [3] - The company is focused on enhancing systems that support scale and pursuing a balanced financing strategy for efficient market entry [3] - Daniel's experience includes leading international subsidiaries and managing supply agreements to ensure operational scale and margin discipline [7]